{"gene":"MICA","run_date":"2026-06-10T02:59:50","timeline":{"discoveries":[{"year":2008,"finding":"MICA ectodomain shedding by tumor cells is mediated by ADAM10 and ADAM17 metalloproteases; silencing of ADAM10 or ADAM17 inhibited proteolytic release of soluble MICA from tumor cells, and the cleavage site maps to the stalk of the MICA ectodomain where deletions (but not alanine substitutions) impede shedding.","method":"siRNA knockdown of ADAM10/ADAM17 in tumor cell lines, small-molecule inhibitor/stimulator assays, ELISA for soluble MICA","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal genetic silencing of two proteases with direct biochemical readout, replicated across multiple tumor cell lines and confirmed with pharmacological inhibitors","pmids":["18676862"],"is_preprint":false},{"year":2018,"finding":"Antibodies targeting the MICA α3 domain (the site of proteolytic shedding) prevent loss of cell-surface MICA and MICB by human cancer cells and restore NKG2D-mediated NK cell immune surveillance; antitumor immunity was mediated mainly by NK cells through NKG2D and CD16 Fc receptors.","method":"Rational antibody design targeting α3 domain, in vitro shedding assays, multiple immunocompetent mouse tumor models, humanized mouse melanoma metastasis model, NK cell depletion experiments","journal":"Science (New York, N.Y.)","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — multiple orthogonal methods (in vitro shedding inhibition, multiple in vivo models, mechanistic NK depletion), single rigorous study with strong evidence","pmids":["29599246"],"is_preprint":false},{"year":2004,"finding":"MICA/NKG2D interaction directly mediates IEL cytotoxicity toward intestinal epithelial cells in celiac disease; gliadin (or its p31-49 peptide) induces MICA expression on gut epithelium via IL-15, which then triggers innate-like cytotoxicity and costimulates CD8 T cells through NKG2D engagement.","method":"In vitro gliadin challenge of intestinal epithelial cells, anti-MICA/NKG2D blocking antibodies, coculture cytotoxicity assays, patient biopsy analysis","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 / Strong — blocking antibody experiments combined with cytotoxicity assays and patient tissue, multiple orthogonal approaches in one study","pmids":["15357948"],"is_preprint":false},{"year":2015,"finding":"The MICA-129Met isoform (strong NKG2D binder) elicits stronger NKG2D signaling, more NK-cell degranulation and IFN-γ release, and faster CD8+ T-cell costimulation than MICA-129Val; MICA-129Met also induces faster and stronger NKG2D downregulation on NK and CD8+ T cells, limiting surface NKG2D levels.","method":"Functional NK cytotoxicity assays, IFN-γ ELISA, flow cytometry for NKG2D surface expression, clinical HSCT cohort (n=452)","journal":"EMBO molecular medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple functional assays (cytotoxicity, IFN-γ, NKG2D downregulation) combined with large clinical cohort validation","pmids":["26483398"],"is_preprint":false},{"year":2015,"finding":"The MICA-129Met/Val dimorphism affects plasma membrane expression and shedding: MICA-129Met variants are retained more in intracellular compartments, and when expressed at the cell surface are more susceptible to proteolytic shedding, resulting in lower net surface MICA-129Met density despite higher mRNA levels.","method":"Flow cytometry for surface MICA on panel of tumor/melanoma cell lines, ELISA for soluble MICA, transfection of MICA-129Met and -Val constructs into MICA-negative melanoma cells, intracellular MICA staining","journal":"Immunogenetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple cell-biological methods in single lab, isogenic transfectant comparison provides mechanistic clarity","pmids":["26585323"],"is_preprint":false},{"year":2011,"finding":"NF-κB regulates MICA transcription in endothelial cells via a defined control site at −130 bp upstream of the MICA transcription start site; TNFα-induced MICA upregulation is mediated through this NF-κB site, which overlaps with a heat shock response element integrating both pathways; lentiviral expression of a dominant-negative truncated HSF1 blocked the TNFα-driven MICA response.","method":"Reporter gene assays, site-directed mutagenesis of MICA promoter, ChIP, lentivirus-mediated gene delivery with dominant-negative HSF1 in primary human endothelial cells, immunohistochemistry of atherosclerotic lesions","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — promoter mutagenesis combined with dominant-negative functional rescue in primary cells, confirmed in patient tissue","pmids":["22170063"],"is_preprint":false},{"year":2008,"finding":"Decreased Dicer expression in human cells upregulates MICA and MICB via activation of the DNA damage response; MICA/B upregulation induced by Dicer knockdown was prevented by pharmacological or genetic inhibition of ATM, ATR, or CHK1, placing MICA/B induction downstream of DNA damage signaling.","method":"RNAi knockdown of Dicer, pharmacological inhibitors of ATM/ATR/CHK1, genetic epistasis with checkpoint kinase mutants, Western blot and flow cytometry for MICA/B","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis with multiple DNA damage pathway components, orthogonal pharmacological confirmation","pmids":["18644891"],"is_preprint":false},{"year":2014,"finding":"MICA-induced NKG2D downregulation on human NK cells is mechanistically distinct from ULBP2-induced downregulation: MICA (but not ULBP2) engages the ubiquitin pathway and the E3 ligase c-Cbl to drive NKG2D internalization and lysosomal/proteasomal degradation.","method":"Comparison of MICA vs. ULBP2 stimulation of NK cells, c-Cbl siRNA knockdown, ubiquitin pathway inhibitors, flow cytometry for NKG2D surface expression and internalization, cytotoxicity assays","journal":"European journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA knockdown of c-Cbl with functional NKG2D readout, single lab, two orthogonal methods","pmids":["24846123"],"is_preprint":false},{"year":2007,"finding":"Mutations designed to destabilize the unbound (disordered) region of MICA—rather than to stabilize the receptor-bound conformation—increased the NKG2D association rate and binding affinity by 0.9–1.8 kcal/mol; kinetic changes were primarily observed during association, consistent with the disordered-to-ordered conformational transition upon receptor binding.","method":"RosettaDesign computational mutagenesis, recombinant protein expression, surface plasmon resonance (SPR) kinetics and thermodynamics","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution with SPR kinetics and thermodynamic analysis on 15+ MICA mutants, single lab but rigorous biophysical approach","pmids":["17690100"],"is_preprint":false},{"year":2002,"finding":"MICA expression on T lymphocytes is induced by T cell activation signals: engagement of CD3 or CD28 (with PMA) upregulates MICA protein and mRNA in both CD4+ and CD8+ T cells, as detected by Western blot, RT-PCR, and flow cytometry; activation reaches plateau at day 3–4.","method":"Anti-CD3 and anti-CD28 antibody stimulation, Western blot, RT-PCR, flow cytometry for surface MICA","journal":"Journal of leukocyte biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — three orthogonal detection methods (Western, RT-PCR, flow cytometry) in single lab","pmids":["11994503"],"is_preprint":false},{"year":2006,"finding":"Activated CD4+ T lymphocytes retain MICA predominantly in intracellular compartments (visualized by confocal microscopy), resulting in low surface MICA expression; this intracellular retention appeared to protect activated CD4+ T cells from NKG2D-mediated NK cell killing, as MICA contribution to NK cytotoxicity was marginal despite inducible MICA protein expression.","method":"Confocal microscopy for intracellular MICA localization, NK cytotoxicity assays with anti-MICA blocking, Western blot, flow cytometry","journal":"Human immunology","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — direct localization by confocal microscopy with functional NK cytotoxicity readout, single lab","pmids":["16698439"],"is_preprint":false},{"year":2012,"finding":"ERp5 (a thiol oxidoreductase) and GRP78, when translocated to the cell surface on chronic lymphocytic leukemia (CLL) cells, co-localize with MICA and are involved in proteolytic MICA shedding; pharmacological inhibition of ERp5 activity reduced soluble MICA release from CLL cells.","method":"Immunofluorescence and flow cytometry co-localization, correlation analysis, pharmacological ERp5 inhibition, ELISA for soluble MICA","journal":"Cancer immunology, immunotherapy : CII","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — co-localization plus pharmacological inhibition providing functional link, single lab","pmids":["22215138"],"is_preprint":false},{"year":2005,"finding":"Tumor-derived exosomes bearing MICA (and other NKG2D ligands) reduce the proportion of NKG2D-expressing CD8+ T cells and CD3− effector cells and impair NKG2D-dependent cytotoxicity; blocking NKG2D ligands on exosomes with antibodies reversed this inhibition, establishing that exosomal MICA mediates immune evasion.","method":"Incubation of PBL with tumor exosomes, flow cytometry for NKG2D surface expression, anti-NKG2D ligand antibody blocking, in vitro cytotoxicity assays","journal":"Blood cells, molecules & diseases","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — antibody blocking experiments on exosome-treated effector cells, functional cytotoxicity assay, single lab","pmids":["15885603"],"is_preprint":false},{"year":2012,"finding":"Hypoxia downregulates cell-surface MICA on osteosarcoma cells in a HIF-1α-dependent manner without increasing soluble MICA; siRNA knockdown of HIF-1α under hypoxia restored surface MICA expression and concomitantly increased soluble MICA, placing HIF-1α upstream of MICA suppression.","method":"Hypoxia chamber culture (1% O2), siRNA knockdown of HIF-1α, flow cytometry for surface MICA, ELISA for soluble MICA, NK cytotoxicity assay","journal":"International journal of oncology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic knockdown of HIF-1α with multiple readouts (surface MICA, soluble MICA, NK killing), single lab","pmids":["22992985"],"is_preprint":false},{"year":2013,"finding":"The MICA*008 A5.1 frameshift allele causes 7–10-fold higher MICA mRNA and surface protein expression on endothelial cells and shifts MICA release exclusively to exosomes rather than enzymatic (metalloproteinase) cleavage; A5.1 endothelial cells elicit enhanced NKG2D interaction and NK-cell-mediated lysis.","method":"Comparative expression analysis of A5.1 vs. wild-type EC, RT-PCR, Western blot, flow cytometry, NKG2D binding assay, NK cytotoxicity assay, exosome isolation","journal":"Journal of the American Society of Nephrology : JASN","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods comparing isogenic variant, single lab","pmids":["23539759"],"is_preprint":false},{"year":2017,"finding":"MICA expression is regulated by purine nucleotide metabolism: active glycolysis and purine synthesis are necessary to upregulate MICA, and increases in purine nucleotide levels alone are sufficient to induce MICA expression, with metabolic induction of MICA directly increasing NKG2D-dependent cytotoxicity.","method":"Metabolic interventions (glucose deprivation, glycolysis inhibitors, purine synthesis inhibitors), metabolomic analyses, flow cytometry for surface MICA, NK cytotoxicity assays","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple metabolic perturbations with MICA expression and functional cytotoxicity readouts, single lab","pmids":["29279329"],"is_preprint":false},{"year":2005,"finding":"MICA can mediate NKG2D-independent suppression of T cell proliferation; this suppressive effect requires IL-10 and involves a receptor other than NKG2D.","method":"T cell proliferation assays with MICA-expressing stimulator cells, NKG2D blocking antibodies, IL-10 neutralization/addition, genetic NKG2D-deficient cells","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — NKG2D blocking and IL-10 neutralization in proliferation assays establishing NKG2D-independent pathway, single lab","pmids":["16091471"],"is_preprint":false},{"year":2008,"finding":"Estradiol upregulates MICA expression on uterine epithelial cells in an estrogen receptor-dependent manner; MICA protein was detected primarily on endometrial epithelial cells with greater expression in the secretory phase of the menstrual cycle.","method":"Estradiol treatment of uterine epithelial cells, estrogen receptor antagonist blocking, real-time PCR, immunohistochemistry of endometrial biopsies","journal":"Clinical immunology (Orlando, Fla.)","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — estrogen receptor antagonist establishes receptor dependence, corroborated by tissue immunohistochemistry, single lab","pmids":["18728002"],"is_preprint":false},{"year":2021,"finding":"The HCMV protein UL147A specifically downregulates the most prevalent MICA allele, MICA*008, by inducing its maturation arrest and additionally targeting it for proteasomal degradation; UL147A specificity for MICA*008 is determined by the non-canonical GPI anchoring pathway used by immature MICA*008.","method":"HCMV infection of cells expressing MICA*008 vs. other alleles, UL147A expression constructs, flow cytometry for surface MICA, proteasome inhibitor assays, mechanistic analysis of GPI pathway dependence","journal":"PLoS pathogens","confidence":"High","confidence_rationale":"Tier 2 / Strong — allele-specific knockdown, mechanistic pathway dissection (maturation arrest + proteasomal degradation + GPI pathway), proteasome inhibitor rescue, multiple orthogonal methods","pmids":["33939764"],"is_preprint":false},{"year":2022,"finding":"The MICA/B antibody 7C6 (targeting the α3 domain to inhibit shedding) promotes macrophage-mediated antibody-dependent phagocytosis of AML cells as the primary mechanism of antitumor efficacy; romidepsin (HDAC inhibitor) increased MICA/B surface expression and synergized with 7C6 to enhance macrophage phagocytosis and reduce leukemia burden.","method":"Macrophage depletion in mouse AML models, antibody-dependent phagocytosis assays, MICA/B expression by flow cytometry following romidepsin treatment, humanized AML mouse model, primary patient AML cells","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Strong — macrophage depletion epistasis, phagocytosis assays, drug combination studies, in vivo and humanized models, multiple orthogonal methods","pmids":["34359073"],"is_preprint":false},{"year":2023,"finding":"MUC1-C represses MICA and MICB expression through NF-κB-driven EZH2-mediated and DNMT-mediated methylation of the MICA/B promoter regions; MUC1-C also regulates ERp5 (required for MICA/B protease digestion and shedding) and interacts with RAB27A (required for exosome formation), thereby controlling both shedding and exosomal MICA/B secretion.","method":"Genetic and pharmacological MUC1-C targeting (GO-203 inhibitor), co-immunoprecipitation for MUC1-C/ERp5 and MUC1-C/RAB27A interactions, direct binding studies, ChIP for H3K27me3 and DNA methylation at MICA/B promoters, ELISA for shed MICA/B, exosome isolation and characterization, NK cytotoxicity assays","journal":"Journal for immunotherapy of cancer","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — multiple orthogonal mechanisms (epigenetic, shedding, exosomal) each validated by distinct methods (ChIP, Co-IP, direct binding, functional rescue), single rigorous study","pmids":["36754452"],"is_preprint":false},{"year":2018,"finding":"ADAM17 is the primary MICA sheddase in hepatocellular carcinoma cells; ADAM17 siRNA knockdown reduced soluble MICA levels and increased membrane-bound MICA; lomofungin enzymatically inhibits ADAM17 and dose-dependently restores membrane MICA while reducing soluble MICA shedding, with effects abolished by ADAM17 knockdown.","method":"siRNA knockdown of ADAM family members, ELISA for soluble MICA, flow cytometry for membrane MICA, in vitro ADAM17 enzymatic inhibition assay with FDA-approved drug library, structure-activity analysis of lomofungin analogs","journal":"International journal of cancer","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — enzymatic assay plus genetic rescue (knockdown abolishes drug effect), multiple cell lines, SAR analysis","pmids":["29873070"],"is_preprint":false},{"year":2013,"finding":"MicroRNAs of the miR-25-93-106b cluster suppress MICA expression in HCC cells; overexpression of this miRNA cluster significantly reduced MICA protein levels, while silencing enhanced MICA expression, with biologically significant effects on NKG2D binding and in vivo NK cell killing.","method":"miRNA overexpression and inhibition in HCC cells, Western blot for MICA, NKG2D-binding assay, in vivo cell-killing model","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — bidirectional miRNA manipulation (overexpression and inhibition) with functional NKG2D and in vivo readouts, single lab","pmids":["24061441"],"is_preprint":false},{"year":2006,"finding":"MICA antigens stimulate T cell proliferation and CD8+ T cell-mediated cytotoxicity in a manner dependent on MHC class I and II molecules but independent of NKG2D; immunization with recombinant MICA elicited a predominantly Th2-type CD4+ T cell response (IL-4 dominant), and MICA-stimulated CD8+ T cells killed MICA-primed target cells.","method":"Mouse immunization with rMICA, [3H]thymidine proliferation assay, CFSE proliferation tracking, cytokine ELISA, MHC class I/II and NKG2D blocking antibodies, cytotoxicity assay","journal":"Human immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — antibody blocking of MHC and NKG2D receptors establishes pathway independence, multiple readouts, single lab","pmids":["16698445"],"is_preprint":false},{"year":2013,"finding":"Endothelial cell MICA expression and shedding are regulated by inflammatory cytokines and proliferative signals: TNFα upregulates surface MICA via NF-κB and MAPK pathways (JNK, ERK1/2, p38); IFNγ decreases surface MICA; both cytokines induce soluble MICA release; FGF-2-driven EC proliferation and wound healing increase surface MICA levels. Glycosylation and metalloproteinase activity are major post-transcriptional mechanisms controlling MICA on ECs.","method":"Cytokine treatment of ECs, NF-κB and MAPK pathway inhibitors, metalloproteinase inhibitors, glycosylation inhibitors, flow cytometry for surface MICA, ELISA for soluble MICA, proliferation assays","journal":"Journal of innate immunity","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple pathway inhibitors with MICA expression and shedding readouts, single lab","pmids":["23860405"],"is_preprint":false},{"year":2010,"finding":"IL-2 induces MICA expression in T lymphocytes through signaling pathways involving Jak3/STAT5, p38 MAPK, p70S6 kinase, Lck/Fyn kinases, and NF-κB, as demonstrated by targeted pharmacological inhibition of each pathway.","method":"Pharmacological inhibition of Jak3, STAT5, p38 MAPK, p70S6K, Lck/Fyn, and NF-κB in IL-2-stimulated T cells; Western blot for MICA protein","journal":"Human immunology","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — pharmacological inhibition of multiple signaling nodes with MICA protein readout, single lab","pmids":["16698439"],"is_preprint":false}],"current_model":"MICA is a stress-inducible MHC class I-related cell-surface glycoprotein that serves as the principal ligand for the activating receptor NKG2D on NK cells, γδ T cells, and CD8+ T cells; its surface expression is transcriptionally upregulated by NF-κB (via TNFα), estradiol, purine metabolic activity, DNA damage (ATM/ATR/CHK1 pathway), and T cell activation signals (CD3/CD28), while being repressed by HIF-1α (under hypoxia), IL-10, and the MUC1-C→EZH2/DNMT epigenetic axis; proteolytic shedding of the MICA ectodomain by ADAM10, ADAM17, and other ADAMs generates immunosuppressive soluble MICA that downregulates NKG2D and enables tumor immune evasion, with shedding further regulated by ERp5 and modulated by the MICA-129Met/Val dimorphism (Met variant shows higher NKG2D binding but greater intracellular retention and surface shedding); MICA-induced NKG2D internalization and degradation is mediated specifically by the E3 ubiquitin ligase c-Cbl, distinguishing MICA from other NKG2D ligands; viral immune evasion of MICA is exemplified by HCMV UL147A, which arrests maturation of the predominant MICA*008 allele and targets it for proteasomal degradation via its non-canonical GPI-anchoring pathway."},"narrative":{"mechanistic_narrative":"MICA is a stress-inducible cell-surface ligand for the activating immunoreceptor NKG2D that couples cellular stress states to NK-cell, γδ T-cell, and CD8+ T-cell cytotoxicity, functioning as a central node in immune surveillance of transformed, infected, and inflamed cells [PMID:15357948, PMID:29279329]. Engagement of NKG2D by MICA drives degranulation, IFN-γ release, and target killing, with the natural MICA-129Met/Val dimorphism tuning the strength of this output: the Met variant binds NKG2D more strongly and elicits faster signaling but also drives more rapid NKG2D downregulation [PMID:26483398]. Structurally, NKG2D binding involves a disordered-to-ordered transition of MICA, and mutations that destabilize the unbound state accelerate association and raise affinity [PMID:17690100]. MICA expression is controlled at multiple levels: it is transcriptionally upregulated by NF-κB downstream of TNFα through a defined promoter element overlapping a heat-shock response element [PMID:22170063], by DNA-damage signaling through the ATM/ATR/CHK1 axis [PMID:18644891], by purine nucleotide metabolism and glycolysis [PMID:29279329], by T-cell activation and IL-2 signaling [PMID:11994503, PMID:16698439], and by estradiol in endometrial epithelium [PMID:18728002], while being repressed by HIF-1α under hypoxia [PMID:22992985], by miR-25-93-106b [PMID:24061441], and by the MUC1-C→NF-κB→EZH2/DNMT epigenetic axis [PMID:36754452]. A dominant route of immune evasion is proteolytic shedding of the MICA ectodomain at its α3/stalk region by ADAM10 and ADAM17, generating soluble MICA that downregulates NKG2D; shedding requires the thiol oxidoreductase ERp5 and is governed by MUC1-C, which also controls exosomal MICA release via RAB27A [PMID:18676862, PMID:22215138, PMID:36754452, PMID:29873070]. MICA additionally contributes to disease pathology, mediating intestinal epithelial cytotoxicity in celiac disease through IL-15-driven induction and NKG2D engagement [PMID:15357948]. Antibodies targeting the α3 shedding site restore surface MICA and reactivate antitumor immunity through NK-cell NKG2D/CD16 effector functions and macrophage-mediated phagocytosis [PMID:29599246, PMID:34359073]. Viral evasion is exemplified by HCMV UL147A, which arrests maturation of the prevalent MICA*008 allele and routes it for proteasomal degradation via its non-canonical GPI-anchoring pathway [PMID:33939764].","teleology":[{"year":2002,"claim":"Established that MICA is not constitutively fixed but is induced as a marker of lymphocyte activation, defining it as a regulated stress/activation ligand rather than a static surface protein.","evidence":"Anti-CD3/CD28 stimulation of CD4+/CD8+ T cells with Western blot, RT-PCR, and flow cytometry","pmids":["11994503"],"confidence":"Medium","gaps":["Does not define the transcription factors linking TCR signaling to the MICA promoter","Surface versus intracellular distribution of induced MICA not resolved"]},{"year":2004,"claim":"Demonstrated that MICA/NKG2D engagement directly drives tissue pathology, linking MICA induction to intestinal epithelial destruction in celiac disease.","evidence":"Gliadin challenge of intestinal epithelium, IL-15 dependence, anti-MICA/NKG2D blocking, coculture cytotoxicity, patient biopsies","pmids":["15357948"],"confidence":"High","gaps":["Transcriptional mechanism of IL-15-driven MICA induction not detailed","Does not address shedding or soluble MICA in this context"]},{"year":2005,"claim":"Revealed two routes by which MICA suppresses immunity beyond direct activation: exosome-borne MICA downregulates effector NKG2D, and a distinct NKG2D-independent, IL-10-dependent pathway suppresses T-cell proliferation.","evidence":"Tumor exosome incubation with PBL plus antibody blocking; MICA stimulator cells with NKG2D blocking and IL-10 neutralization","pmids":["15885603","16091471"],"confidence":"Medium","gaps":["Identity of the non-NKG2D MICA receptor unknown","Mechanism of MICA loading onto exosomes not defined"]},{"year":2006,"claim":"Showed MICA can act as an immunogen engaging adaptive responses through MHC class I/II independent of NKG2D, and that activated CD4+ T cells sequester MICA intracellularly to evade NK killing.","evidence":"rMICA immunization with proliferation/cytotoxicity assays and MHC/NKG2D blocking; confocal microscopy of intracellular MICA with NK cytotoxicity","pmids":["16698445","16698439"],"confidence":"Medium","gaps":["Mechanism of intracellular retention not defined","Adaptive MICA antigen presentation pathway not molecularly mapped"]},{"year":2007,"claim":"Defined the biophysical basis of MICA-NKG2D recognition, showing the unbound MICA surface is disordered and that the association step is rate-limiting via a disorder-to-order transition.","evidence":"RosettaDesign mutagenesis of 15+ mutants with SPR kinetics and thermodynamics","pmids":["17690100"],"confidence":"High","gaps":["In vitro biophysics only; cellular relevance of designed mutants untested","Does not address allelic affinity differences in physiological context"]},{"year":2008,"claim":"Identified ADAM10 and ADAM17 as the proteases that shed MICA at its stalk, establishing the molecular machinery of soluble MICA generation and tumor immune evasion.","evidence":"Reciprocal siRNA knockdown of ADAM10/ADAM17, inhibitor assays, stalk deletion mapping, soluble MICA ELISA","pmids":["18676862"],"confidence":"High","gaps":["Does not define what triggers protease engagement of MICA","Relative contribution of each ADAM across tissues unresolved"]},{"year":2008,"claim":"Connected MICA induction to genome-instability sensing and to hormonal control, showing DNA damage signaling (ATM/ATR/CHK1) and estrogen-receptor signaling each upregulate MICA.","evidence":"Dicer knockdown with ATM/ATR/CHK1 inhibition and epistasis; estradiol treatment of uterine epithelium with ER antagonist and immunohistochemistry","pmids":["18644891","18728002"],"confidence":"High","gaps":["Transcription factors executing DNA-damage-driven MICA induction not identified","Estrogen-responsive promoter elements not mapped"]},{"year":2011,"claim":"Mapped a defined NF-κB control site at -130 bp mediating TNFα-driven MICA transcription and showed it integrates with heat-shock signaling, providing a transcriptional mechanism for inflammatory MICA induction.","evidence":"Promoter reporter assays, site-directed mutagenesis, ChIP, dominant-negative HSF1 in primary endothelial cells, atherosclerotic lesion immunohistochemistry","pmids":["22170063"],"confidence":"High","gaps":["Does not address how this site interacts with other inducers (DNA damage, metabolism)","Cell-type generality of the -130 element beyond endothelium not tested"]},{"year":2012,"claim":"Established additional shedding and repression mechanisms: ERp5/GRP78 surface translocation enables MICA shedding on CLL cells, and HIF-1α suppresses surface MICA under hypoxia.","evidence":"Co-localization and ERp5 pharmacological inhibition with soluble MICA ELISA; hypoxia culture with HIF-1α siRNA and surface/soluble MICA readouts","pmids":["22215138","22992985"],"confidence":"Medium","gaps":["Mechanism linking ERp5 redox activity to ADAM cleavage not defined","HIF-1α acts transcriptionally or post-transcriptionally on MICA not resolved"]},{"year":2013,"claim":"Showed allele- and regulator-specific control of MICA fate, with the MICA*008 A5.1 frameshift diverting release to exosomes and the miR-25-93-106b cluster post-transcriptionally suppressing MICA.","evidence":"Comparative A5.1 vs wild-type endothelial expression with NK assays; bidirectional miRNA manipulation in HCC with NKG2D-binding and in vivo killing","pmids":["23539759","24061441"],"confidence":"Medium","gaps":["Determinants channeling A5.1 MICA to exosomes versus protease cleavage not defined","Direct miRNA-MICA mRNA binding sites not mapped"]},{"year":2013,"claim":"Integrated endothelial MICA regulation, showing TNFα upregulates MICA via NF-κB/MAPK while IFNγ lowers it, with glycosylation and metalloproteinase activity as dominant post-transcriptional controls.","evidence":"Cytokine treatment of endothelial cells with NF-κB/MAPK, metalloproteinase, and glycosylation inhibitors; surface and soluble MICA readouts","pmids":["23860405"],"confidence":"Medium","gaps":["Specific MAPK targets on the MICA promoter not identified","Glycosylation sites controlling MICA stability not mapped"]},{"year":2014,"claim":"Distinguished MICA from other NKG2D ligands mechanistically, showing MICA uniquely recruits the ubiquitin pathway and c-Cbl to drive NKG2D internalization and degradation.","evidence":"MICA vs ULBP2 NK stimulation, c-Cbl siRNA, ubiquitin pathway inhibitors, NKG2D internalization flow cytometry, cytotoxicity","pmids":["24846123"],"confidence":"Medium","gaps":["Direct c-Cbl substrate ubiquitination of NKG2D not biochemically demonstrated","Why MICA but not ULBP2 engages c-Cbl is unexplained"]},{"year":2015,"claim":"Defined the functional consequences of the MICA-129Met/Val dimorphism, linking the Met variant's stronger NKG2D binding to faster signaling but greater NKG2D downregulation, intracellular retention, and shedding.","evidence":"NK cytotoxicity/IFN-γ assays, NKG2D flow cytometry, HSCT cohort (n=452); isogenic Met/Val transfectants with surface/soluble/intracellular MICA readouts","pmids":["26483398","26585323"],"confidence":"High","gaps":["Structural basis of Met-driven intracellular retention not defined","Interaction of dimorphism with allele-specific shedding routes unresolved"]},{"year":2017,"claim":"Linked metabolic state to immune visibility, showing glycolysis and purine nucleotide synthesis are necessary and sufficient to induce MICA and enhance NKG2D-dependent killing.","evidence":"Metabolic inhibitors, metabolomics, surface MICA flow cytometry, NK cytotoxicity","pmids":["29279329"],"confidence":"Medium","gaps":["Signaling that couples purine levels to MICA transcription not identified","Whether metabolic induction is transcriptional or post-transcriptional unresolved"]},{"year":2018,"claim":"Provided proof-of-concept that blocking MICA shedding at the α3 domain restores immune surveillance, and confirmed ADAM17 as the dominant sheddase in hepatocellular carcinoma with a druggable inhibitor.","evidence":"Rational α3-domain antibody with in vitro shedding inhibition and multiple in vivo tumor models plus NK depletion; ADAM17 siRNA and lomofungin enzymatic inhibition with knockdown-abolished rescue","pmids":["29599246","29873070"],"confidence":"High","gaps":["Tissue-specific dominance of ADAM17 vs ADAM10 not generalized","Long-term resistance to shedding blockade not addressed"]},{"year":2021,"claim":"Defined an allele-specific viral evasion mechanism in which HCMV UL147A exploits the non-canonical GPI-anchoring pathway of MICA*008 to arrest its maturation and trigger proteasomal degradation.","evidence":"HCMV infection across MICA alleles, UL147A constructs, surface MICA flow cytometry, proteasome inhibitor rescue, GPI pathway dependence analysis","pmids":["33939764"],"confidence":"High","gaps":["Molecular interface between UL147A and immature MICA*008 not resolved","Generalization to other MICA alleles using canonical anchoring not addressed"]},{"year":2022,"claim":"Expanded the effector mechanism of MICA-targeting therapy, showing α3-domain antibody 7C6 acts primarily through macrophage antibody-dependent phagocytosis and synergizes with HDAC inhibition to raise MICA/B.","evidence":"Macrophage depletion in AML models, ADCP assays, romidepsin-induced MICA/B expression, humanized AML model, primary patient cells","pmids":["34359073"],"confidence":"High","gaps":["Relative contribution of macrophage versus NK effector arms across tumor types unresolved","Mechanism of romidepsin-driven MICA/B upregulation not molecularly defined"]},{"year":2023,"claim":"Unified transcriptional repression, shedding, and exosomal secretion under a single oncogenic regulator, showing MUC1-C represses MICA/B via NF-κB/EZH2/DNMT methylation while controlling ERp5-dependent shedding and RAB27A-dependent exosomal release.","evidence":"MUC1-C genetic/pharmacological targeting, ChIP for H3K27me3 and DNA methylation, Co-IP and direct binding for MUC1-C/ERp5 and MUC1-C/RAB27A, soluble/exosomal MICA assays, NK cytotoxicity","pmids":["36754452"],"confidence":"High","gaps":["Direct recruitment of EZH2/DNMT to the MICA/B promoter by MUC1-C not structurally resolved","Hierarchy among the three MUC1-C-controlled mechanisms in vivo not established"]},{"year":null,"claim":"The identity of the non-NKG2D MICA receptor mediating IL-10-dependent T-cell suppression and the molecular determinants that select between protease shedding versus exosomal release remain unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No molecular identification of the NKG2D-independent MICA receptor","Switch governing exosomal versus enzymatic MICA release not defined","Integration of the many transcriptional inducers/repressors at the MICA locus not unified"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[2,3,8]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[2,3]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[0,3,13,14]},{"term_id":"GO:0031410","term_label":"cytoplasmic vesicle","supporting_discovery_ids":[12,14,20]},{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[0,11,21]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[1,2,3,19]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[18,20,2]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[5,20]}],"complexes":[],"partners":["NKG2D","ADAM10","ADAM17","ERP5","C-CBL","MUC1-C","RAB27A","GRP78"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q29983","full_name":"MHC class I polypeptide-related sequence A","aliases":[],"length_aa":383,"mass_kda":42.9,"function":"Widely expressed membrane-bound protein which acts as a ligand to stimulate an activating receptor KLRK1/NKG2D, expressed on the surface of essentially all human natural killer (NK), gammadelta T and CD8 alphabeta T-cells (PubMed:11491531, PubMed:11777960). Up-regulated in stressed conditions, such as viral and bacterial infections or DNA damage response, serves as signal of cellular stress, and engagement of KLRK1/NKG2D by MICA triggers NK-cells resulting in a range of immune effector functions, such as cytotoxicity and cytokine production (PubMed:10426993)","subcellular_location":"Cell membrane; Cytoplasm","url":"https://www.uniprot.org/uniprotkb/Q29983/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/MICA","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/MICA","total_profiled":1310},"omim":[{"mim_id":"611817","title":"KILLER CELL LECTIN-LIKE RECEPTOR, SUBFAMILY K, MEMBER 1; KLRK1","url":"https://www.omim.org/entry/611817"},{"mim_id":"611184","title":"PIEZO-TYPE MECHANOSENSITIVE ION CHANNEL COMPONENT 1; PIEZO1","url":"https://www.omim.org/entry/611184"},{"mim_id":"611099","title":"PROTEIN DISULFIDE ISOMERASE, FAMILY A, MEMBER 6; PDIA6","url":"https://www.omim.org/entry/611099"},{"mim_id":"605699","title":"UL16-BINDING PROTEIN 3; ULBP3","url":"https://www.omim.org/entry/605699"},{"mim_id":"605698","title":"UL16-BINDING PROTEIN 2; ULBP2","url":"https://www.omim.org/entry/605698"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in many","driving_tissues":[],"url":"https://www.proteinatlas.org/search/MICA"},"hgnc":{"alias_symbol":["PERB11.1"],"prev_symbol":[]},"alphafold":{"accession":"Q29983","domains":[{"cath_id":"3.30.500.10","chopping":"27-202","consensus_level":"high","plddt":92.069,"start":27,"end":202},{"cath_id":"2.60.40.10","chopping":"209-295","consensus_level":"high","plddt":94.3608,"start":209,"end":295}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q29983","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q29983-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q29983-F1-predicted_aligned_error_v6.png","plddt_mean":81.69},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=MICA","jax_strain_url":"https://www.jax.org/strain/search?query=MICA"},"sequence":{"accession":"Q29983","fasta_url":"https://rest.uniprot.org/uniprotkb/Q29983.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q29983/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q29983"}},"corpus_meta":[{"pmid":"15357948","id":"PMC_15357948","title":"A direct role for NKG2D/MICA interaction in villous atrophy during celiac disease.","date":"2004","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/15357948","citation_count":542,"is_preprint":false},{"pmid":"29599246","id":"PMC_29599246","title":"Antibody-mediated inhibition of MICA and MICB shedding promotes NK cell-driven tumor immunity.","date":"2018","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/29599246","citation_count":387,"is_preprint":false},{"pmid":"18676862","id":"PMC_18676862","title":"Tumor-associated MICA is shed by ADAM proteases.","date":"2008","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/18676862","citation_count":307,"is_preprint":false},{"pmid":"8785352","id":"PMC_8785352","title":"DNA binding to mica correlates with cationic radius: assay by atomic force microscopy.","date":"1996","source":"Biophysical journal","url":"https://pubmed.ncbi.nlm.nih.gov/8785352","citation_count":238,"is_preprint":false},{"pmid":"12569559","id":"PMC_12569559","title":"Expression and role of MICA and MICB in human hepatocellular carcinomas and their regulation by retinoic acid.","date":"2003","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/12569559","citation_count":196,"is_preprint":false},{"pmid":"14695218","id":"PMC_14695218","title":"MICA/NKG2D-mediated immunogene therapy of experimental gliomas.","date":"2003","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/14695218","citation_count":171,"is_preprint":false},{"pmid":"11429322","id":"PMC_11429322","title":"MICA and MICB genes: can the enigma of their polymorphism be resolved?","date":"2001","source":"Trends in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/11429322","citation_count":161,"is_preprint":false},{"pmid":"10363723","id":"PMC_10363723","title":"Differential surface expression of MICA by endothelial cells, fibroblasts, keratinocytes, and monocytes.","date":"1999","source":"Human immunology","url":"https://pubmed.ncbi.nlm.nih.gov/10363723","citation_count":122,"is_preprint":false},{"pmid":"33363734","id":"PMC_33363734","title":"NKG2D and MICA/B shedding: a 'tag game' between NK cells and malignant cells.","date":"2020","source":"Clinical & translational immunology","url":"https://pubmed.ncbi.nlm.nih.gov/33363734","citation_count":121,"is_preprint":false},{"pmid":"15885603","id":"PMC_15885603","title":"Exosomes and the MICA-NKG2D system in cancer.","date":"2005","source":"Blood cells, molecules & diseases","url":"https://pubmed.ncbi.nlm.nih.gov/15885603","citation_count":120,"is_preprint":false},{"pmid":"9153324","id":"PMC_9153324","title":"AFM analysis of DNA-protamine complexes bound to mica.","date":"1997","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/9153324","citation_count":119,"is_preprint":false},{"pmid":"11194237","id":"PMC_11194237","title":"MICA polymorphism is associated with type 1 diabetes in the Korean population.","date":"2001","source":"Diabetes care","url":"https://pubmed.ncbi.nlm.nih.gov/11194237","citation_count":111,"is_preprint":false},{"pmid":"17511763","id":"PMC_17511763","title":"The relationship of anti-MICA antibodies and MICA expression with heart allograft rejection.","date":"2007","source":"American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons","url":"https://pubmed.ncbi.nlm.nih.gov/17511763","citation_count":94,"is_preprint":false},{"pmid":"23027008","id":"PMC_23027008","title":"Mica functionalization for imaging of DNA and protein-DNA complexes with atomic force microscopy.","date":"2013","source":"Methods in molecular biology (Clifton, N.J.)","url":"https://pubmed.ncbi.nlm.nih.gov/23027008","citation_count":92,"is_preprint":false},{"pmid":"20345657","id":"PMC_20345657","title":"MicA sRNA links the PhoP regulon to cell envelope stress.","date":"2010","source":"Molecular microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/20345657","citation_count":91,"is_preprint":false},{"pmid":"17267407","id":"PMC_17267407","title":"Sigma E controls biogenesis of the antisense RNA MicA.","date":"2007","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/17267407","citation_count":90,"is_preprint":false},{"pmid":"19786616","id":"PMC_19786616","title":"MICA-129 genotype, soluble MICA, and anti-MICA antibodies as biomarkers of chronic graft-versus-host disease.","date":"2009","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/19786616","citation_count":86,"is_preprint":false},{"pmid":"17565371","id":"PMC_17565371","title":"In vivo expression pattern of MICA and MICB and its relevance to auto-immunity and cancer.","date":"2007","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/17565371","citation_count":83,"is_preprint":false},{"pmid":"20153697","id":"PMC_20153697","title":"MICA polymorphism: biology and importance in immunity and disease.","date":"2010","source":"Trends in molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/20153697","citation_count":83,"is_preprint":false},{"pmid":"10440244","id":"PMC_10440244","title":"Association of MICA gene and HLA-B*5101 with Behçet's disease in Greece.","date":"1999","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/10440244","citation_count":76,"is_preprint":false},{"pmid":"25330802","id":"PMC_25330802","title":"MICA polymorphism: biology and importance in cancer.","date":"2014","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/25330802","citation_count":74,"is_preprint":false},{"pmid":"26483398","id":"PMC_26483398","title":"The MICA-129 dimorphism affects NKG2D signaling and outcome of hematopoietic stem cell transplantation.","date":"2015","source":"EMBO molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26483398","citation_count":69,"is_preprint":false},{"pmid":"18644891","id":"PMC_18644891","title":"Decreased Dicer expression elicits DNA damage and up-regulation of MICA and MICB.","date":"2008","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/18644891","citation_count":68,"is_preprint":false},{"pmid":"11994503","id":"PMC_11994503","title":"Activation-induced expression of MICA on T lymphocytes involves engagement of CD3 and CD28.","date":"2002","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/11994503","citation_count":68,"is_preprint":false},{"pmid":"21138960","id":"PMC_21138960","title":"Regulation of the small regulatory RNA MicA by ribonuclease III: a target-dependent pathway.","date":"2010","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/21138960","citation_count":67,"is_preprint":false},{"pmid":"11502807","id":"PMC_11502807","title":"Two distinct MICA gene markers discriminate major autoimmune diabetes types.","date":"2001","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/11502807","citation_count":66,"is_preprint":false},{"pmid":"12022360","id":"PMC_12022360","title":"MICA rather than MICB, TNFA, or HLA-DRB1 is associated with susceptibility to psoriatic arthritis.","date":"2002","source":"The Journal of rheumatology","url":"https://pubmed.ncbi.nlm.nih.gov/12022360","citation_count":58,"is_preprint":false},{"pmid":"22170063","id":"PMC_22170063","title":"NF-κB regulates MICA gene transcription in endothelial cell through a genetically inhibitable control site.","date":"2011","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22170063","citation_count":54,"is_preprint":false},{"pmid":"22992985","id":"PMC_22992985","title":"Hypoxia downregulates the expression of cell surface MICA without increasing soluble MICA in osteosarcoma cells in a HIF-1α-dependent manner.","date":"2012","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/22992985","citation_count":51,"is_preprint":false},{"pmid":"30938988","id":"PMC_30938988","title":"Imaging DNA Equilibrated onto Mica in Liquid Using Biochemically Relevant Deposition Conditions.","date":"2019","source":"ACS nano","url":"https://pubmed.ncbi.nlm.nih.gov/30938988","citation_count":48,"is_preprint":false},{"pmid":"26585323","id":"PMC_26585323","title":"The MICA-129Met/Val dimorphism affects plasma membrane expression and shedding of the NKG2D ligand MICA.","date":"2015","source":"Immunogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/26585323","citation_count":47,"is_preprint":false},{"pmid":"11696220","id":"PMC_11696220","title":"Diversity of MICA (PERB11.1) and HLA haplotypes in Northeastern Thais.","date":"2001","source":"Tissue antigens","url":"https://pubmed.ncbi.nlm.nih.gov/11696220","citation_count":45,"is_preprint":false},{"pmid":"20152875","id":"PMC_20152875","title":"Association analysis of MICA gene polymorphism and MICA-129 dimorphism with inflammatory bowel disease susceptibility in a Spanish population.","date":"2010","source":"Human immunology","url":"https://pubmed.ncbi.nlm.nih.gov/20152875","citation_count":45,"is_preprint":false},{"pmid":"25270965","id":"PMC_25270965","title":"MICA SNPs and the NKG2D system in virus-induced HCC.","date":"2014","source":"Journal of gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/25270965","citation_count":44,"is_preprint":false},{"pmid":"28018354","id":"PMC_28018354","title":"Impact of the MICA-129Met/Val Dimorphism on NKG2D-Mediated Biological Functions and Disease Risks.","date":"2016","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/28018354","citation_count":44,"is_preprint":false},{"pmid":"11782275","id":"PMC_11782275","title":"MICA, MICB and C1_4_1 polymorphism in Crohn's disease and ulcerative colitis.","date":"2001","source":"Tissue antigens","url":"https://pubmed.ncbi.nlm.nih.gov/11782275","citation_count":44,"is_preprint":false},{"pmid":"24075503","id":"PMC_24075503","title":"HLA and MICA allosensitization patterns among patients supported by ventricular assist devices.","date":"2013","source":"The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation","url":"https://pubmed.ncbi.nlm.nih.gov/24075503","citation_count":44,"is_preprint":false},{"pmid":"23727634","id":"PMC_23727634","title":"MICA, a gene contributing strong susceptibility to ankylosing spondylitis.","date":"2013","source":"Annals of the rheumatic diseases","url":"https://pubmed.ncbi.nlm.nih.gov/23727634","citation_count":43,"is_preprint":false},{"pmid":"28293239","id":"PMC_28293239","title":"Major Histocompatibility Complex Class I Chain-Related A (MICA) Molecules: Relevance in Solid Organ Transplantation.","date":"2017","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/28293239","citation_count":43,"is_preprint":false},{"pmid":"24846123","id":"PMC_24846123","title":"c-Cbl regulates MICA- but not ULBP2-induced NKG2D down-modulation in human NK cells.","date":"2014","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/24846123","citation_count":42,"is_preprint":false},{"pmid":"26791237","id":"PMC_26791237","title":"A bispecific protein rG7S-MICA recruits natural killer cells and enhances NKG2D-mediated immunosurveillance against hepatocellular carcinoma.","date":"2016","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/26791237","citation_count":41,"is_preprint":false},{"pmid":"29765374","id":"PMC_29765374","title":"MICA-129 Dimorphism and Soluble MICA Are Associated With the Progression of Multiple Myeloma.","date":"2018","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/29765374","citation_count":40,"is_preprint":false},{"pmid":"34359073","id":"PMC_34359073","title":"MICA/B antibody induces macrophage-mediated immunity against acute myeloid leukemia.","date":"2022","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/34359073","citation_count":39,"is_preprint":false},{"pmid":"35288692","id":"PMC_35288692","title":"The MHC class I MICA gene is a histocompatibility antigen in kidney transplantation.","date":"2022","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35288692","citation_count":38,"is_preprint":false},{"pmid":"24061441","id":"PMC_24061441","title":"Regulation of the expression of the liver cancer susceptibility gene MICA by microRNAs.","date":"2013","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/24061441","citation_count":38,"is_preprint":false},{"pmid":"22215138","id":"PMC_22215138","title":"Expression of ERp5 and GRP78 on the membrane of chronic lymphocytic leukemia cells: association with soluble MICA shedding.","date":"2012","source":"Cancer immunology, immunotherapy : CII","url":"https://pubmed.ncbi.nlm.nih.gov/22215138","citation_count":38,"is_preprint":false},{"pmid":"10803866","id":"PMC_10803866","title":"Polymorphism in the transmembrane region of the MICA gene and type 1 diabetes.","date":"2000","source":"Journal of pediatric endocrinology & metabolism : JPEM","url":"https://pubmed.ncbi.nlm.nih.gov/10803866","citation_count":38,"is_preprint":false},{"pmid":"19363685","id":"PMC_19363685","title":"MICA polymorphisms and decreased expression of the MICA receptor NKG2D contribute to idiopathic pulmonary fibrosis susceptibility.","date":"2009","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19363685","citation_count":37,"is_preprint":false},{"pmid":"32153595","id":"PMC_32153595","title":"High-Throughput MICA/B Genotyping of Over Two Million Samples: Workflow and Allele Frequencies.","date":"2020","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/32153595","citation_count":36,"is_preprint":false},{"pmid":"31193050","id":"PMC_31193050","title":"Catalytic, kinetic and thermodynamic properties of free and immobilized caseinase on mica glass-ceramics.","date":"2019","source":"Heliyon","url":"https://pubmed.ncbi.nlm.nih.gov/31193050","citation_count":35,"is_preprint":false},{"pmid":"21762746","id":"PMC_21762746","title":"Association of MICA and MICB alleles with symptomatic dengue infection.","date":"2011","source":"Human immunology","url":"https://pubmed.ncbi.nlm.nih.gov/21762746","citation_count":34,"is_preprint":false},{"pmid":"18951065","id":"PMC_18951065","title":"Relationship between soluble MICA and the MICA A5.1 homozygous genotype in patients with oral squamous cell carcinoma.","date":"2008","source":"Clinical immunology (Orlando, Fla.)","url":"https://pubmed.ncbi.nlm.nih.gov/18951065","citation_count":34,"is_preprint":false},{"pmid":"9951809","id":"PMC_9951809","title":"MICA gene polymorphism in Takayasu's arteritis and Buerger's disease.","date":"1998","source":"International journal of cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/9951809","citation_count":33,"is_preprint":false},{"pmid":"32010486","id":"PMC_32010486","title":"Tumor-Derived Soluble MICA Obstructs the NKG2D Pathway to Restrain NK Cytotoxicity.","date":"2020","source":"Aging and disease","url":"https://pubmed.ncbi.nlm.nih.gov/32010486","citation_count":33,"is_preprint":false},{"pmid":"18718856","id":"PMC_18718856","title":"Allelic diversity of MICA gene and MICA/HLA-B haplotypic variation in a population of the Murcia region in southeastern Spain.","date":"2008","source":"Human immunology","url":"https://pubmed.ncbi.nlm.nih.gov/18718856","citation_count":33,"is_preprint":false},{"pmid":"16698439","id":"PMC_16698439","title":"Intracellular expression of MICA in activated CD4 T lymphocytes and protection from NK cell-mediated MICA-dependent cytotoxicity.","date":"2006","source":"Human immunology","url":"https://pubmed.ncbi.nlm.nih.gov/16698439","citation_count":32,"is_preprint":false},{"pmid":"20696027","id":"PMC_20696027","title":"Role of MICA in the immune response to transplants.","date":"2010","source":"Tissue antigens","url":"https://pubmed.ncbi.nlm.nih.gov/20696027","citation_count":31,"is_preprint":false},{"pmid":"23539759","id":"PMC_23539759","title":"MICA variant promotes allosensitization after kidney transplantation.","date":"2013","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/23539759","citation_count":31,"is_preprint":false},{"pmid":"29873070","id":"PMC_29873070","title":"Enzymatic inhibition of MICA sheddase ADAM17 by lomofungin in hepatocellular carcinoma cells.","date":"2018","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/29873070","citation_count":31,"is_preprint":false},{"pmid":"11841487","id":"PMC_11841487","title":"Further polymorphism of the MICA gene.","date":"2002","source":"European journal of immunogenetics : official journal of the British Society for Histocompatibility and Immunogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/11841487","citation_count":30,"is_preprint":false},{"pmid":"16091471","id":"PMC_16091471","title":"NKG2D-independent suppression of T cell proliferation by H60 and MICA.","date":"2005","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/16091471","citation_count":29,"is_preprint":false},{"pmid":"23936864","id":"PMC_23936864","title":"Role of HLA, KIR, MICA, and cytokines genes in leprosy.","date":"2013","source":"BioMed research international","url":"https://pubmed.ncbi.nlm.nih.gov/23936864","citation_count":28,"is_preprint":false},{"pmid":"20714339","id":"PMC_20714339","title":"Interleukin 10 decreases MICA expression on melanoma cell surface.","date":"2010","source":"Immunology and cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/20714339","citation_count":28,"is_preprint":false},{"pmid":"21477352","id":"PMC_21477352","title":"Expression of MICA, MICB and NKG2D in human leukemic myelomonocytic and cervical cancer cells.","date":"2011","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/21477352","citation_count":28,"is_preprint":false},{"pmid":"36754452","id":"PMC_36754452","title":"MUC1-C is a master regulator of MICA/B NKG2D ligand and exosome secretion in human cancer cells.","date":"2023","source":"Journal for immunotherapy of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/36754452","citation_count":28,"is_preprint":false},{"pmid":"23860405","id":"PMC_23860405","title":"Endothelial cell activation and proliferation modulate NKG2D activity by regulating MICA expression and shedding.","date":"2013","source":"Journal of innate immunity","url":"https://pubmed.ncbi.nlm.nih.gov/23860405","citation_count":26,"is_preprint":false},{"pmid":"25676333","id":"PMC_25676333","title":"Study of DNA adsorption on mica surfaces using a surface force apparatus.","date":"2015","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/25676333","citation_count":26,"is_preprint":false},{"pmid":"10566597","id":"PMC_10566597","title":"MICA gene polymorphism and the risk to develop cervical intraepithelial neoplasia.","date":"1999","source":"Human immunology","url":"https://pubmed.ncbi.nlm.nih.gov/10566597","citation_count":26,"is_preprint":false},{"pmid":"17157214","id":"PMC_17157214","title":"Post-transplant soluble MICA and MICA antibodies predict subsequent heart graft outcome.","date":"2006","source":"Transplant immunology","url":"https://pubmed.ncbi.nlm.nih.gov/17157214","citation_count":25,"is_preprint":false},{"pmid":"16698445","id":"PMC_16698445","title":"MICA antigens stimulate T cell proliferation and cell-mediated cytotoxicity.","date":"2006","source":"Human immunology","url":"https://pubmed.ncbi.nlm.nih.gov/16698445","citation_count":25,"is_preprint":false},{"pmid":"29279329","id":"PMC_29279329","title":"Purine nucleotide metabolism regulates expression of the human immune ligand MICA.","date":"2017","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/29279329","citation_count":25,"is_preprint":false},{"pmid":"19791748","id":"PMC_19791748","title":"Specific DNA-protein interactions on mica investigated by atomic force microscopy.","date":"2010","source":"Langmuir : the ACS journal of surfaces and colloids","url":"https://pubmed.ncbi.nlm.nih.gov/19791748","citation_count":25,"is_preprint":false},{"pmid":"17911424","id":"PMC_17911424","title":"MICA gene polymorphism in the pathogenesis of type 1 diabetes.","date":"2007","source":"Annals of the New York Academy of Sciences","url":"https://pubmed.ncbi.nlm.nih.gov/17911424","citation_count":25,"is_preprint":false},{"pmid":"32518090","id":"PMC_32518090","title":"Restoration of antitumor immunity through anti-MICA antibodies elicited with a chimeric protein.","date":"2020","source":"Journal for immunotherapy of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/32518090","citation_count":25,"is_preprint":false},{"pmid":"17690100","id":"PMC_17690100","title":"Mutations designed to destabilize the receptor-bound conformation increase MICA-NKG2D association rate and affinity.","date":"2007","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17690100","citation_count":25,"is_preprint":false},{"pmid":"16857416","id":"PMC_16857416","title":"HLA and MICA associations with head and neck squamous cell carcinoma.","date":"2006","source":"Oral oncology","url":"https://pubmed.ncbi.nlm.nih.gov/16857416","citation_count":23,"is_preprint":false},{"pmid":"14675133","id":"PMC_14675133","title":"Polymorphism of the MICA gene and risk for oral submucous fibrosis.","date":"2004","source":"Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology","url":"https://pubmed.ncbi.nlm.nih.gov/14675133","citation_count":23,"is_preprint":false},{"pmid":"18728002","id":"PMC_18728002","title":"Estradiol regulates MICA expression in human endometrial cells.","date":"2008","source":"Clinical immunology (Orlando, Fla.)","url":"https://pubmed.ncbi.nlm.nih.gov/18728002","citation_count":21,"is_preprint":false},{"pmid":"19193353","id":"PMC_19193353","title":"Expression of HLA-G and MICA mRNA in renal allograft.","date":"2009","source":"Transplant immunology","url":"https://pubmed.ncbi.nlm.nih.gov/19193353","citation_count":21,"is_preprint":false},{"pmid":"24962621","id":"PMC_24962621","title":"Diversity and characterization of polymorphic 5' promoter haplotypes of MICA and MICB genes.","date":"2014","source":"Tissue antigens","url":"https://pubmed.ncbi.nlm.nih.gov/24962621","citation_count":21,"is_preprint":false},{"pmid":"31754211","id":"PMC_31754211","title":"LINC01149 variant modulates MICA expression that facilitates hepatitis B virus spontaneous recovery but increases hepatocellular carcinoma risk.","date":"2019","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/31754211","citation_count":20,"is_preprint":false},{"pmid":"21554252","id":"PMC_21554252","title":"MICB polymorphisms and haplotypes with MICA and HLA alleles in Koreans.","date":"2011","source":"Tissue antigens","url":"https://pubmed.ncbi.nlm.nih.gov/21554252","citation_count":20,"is_preprint":false},{"pmid":"15029237","id":"PMC_15029237","title":"MICA and recovery from hepatitis C virus and hepatitis B virus infections.","date":"2004","source":"Genes and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/15029237","citation_count":20,"is_preprint":false},{"pmid":"32683508","id":"PMC_32683508","title":"Leukotriene receptor antagonists enhance HCC treatment efficacy by inhibiting ADAMs and suppressing MICA shedding.","date":"2020","source":"Cancer immunology, immunotherapy : CII","url":"https://pubmed.ncbi.nlm.nih.gov/32683508","citation_count":19,"is_preprint":false},{"pmid":"24372774","id":"PMC_24372774","title":"Role of MICA antibodies in solid organ transplantation.","date":"2013","source":"Clinical transplantation","url":"https://pubmed.ncbi.nlm.nih.gov/24372774","citation_count":18,"is_preprint":false},{"pmid":"17181741","id":"PMC_17181741","title":"MICA and MICB overexpression in oral squamous cell carcinoma.","date":"2007","source":"Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology","url":"https://pubmed.ncbi.nlm.nih.gov/17181741","citation_count":18,"is_preprint":false},{"pmid":"19895570","id":"PMC_19895570","title":"MICA polymorphisms and haplotypes with HLA-B and HLA-DRB1 in Koreans.","date":"2009","source":"Tissue antigens","url":"https://pubmed.ncbi.nlm.nih.gov/19895570","citation_count":18,"is_preprint":false},{"pmid":"36227341","id":"PMC_36227341","title":"αVEGFR2-MICA fusion antibodies enhance immunotherapy effect and synergize with PD-1 blockade.","date":"2022","source":"Cancer immunology, immunotherapy : CII","url":"https://pubmed.ncbi.nlm.nih.gov/36227341","citation_count":17,"is_preprint":false},{"pmid":"23792058","id":"PMC_23792058","title":"HLA and MICA polymorphism in Polynesians and New Zealand Maori: implications for ancestry and health.","date":"2013","source":"Human immunology","url":"https://pubmed.ncbi.nlm.nih.gov/23792058","citation_count":17,"is_preprint":false},{"pmid":"12584051","id":"PMC_12584051","title":"Up-regulated expression of MICA and proinflammatory cytokines in skin biopsies from patients with seborrhoeic dermatitis.","date":"2003","source":"Clinical immunology (Orlando, Fla.)","url":"https://pubmed.ncbi.nlm.nih.gov/12584051","citation_count":17,"is_preprint":false},{"pmid":"33939764","id":"PMC_33939764","title":"The human cytomegalovirus protein UL147A downregulates the most prevalent MICA allele: MICA*008, to evade NK cell-mediated killing.","date":"2021","source":"PLoS pathogens","url":"https://pubmed.ncbi.nlm.nih.gov/33939764","citation_count":17,"is_preprint":false},{"pmid":"29709515","id":"PMC_29709515","title":"5-Methoxyindole-2-carboxylic acid (MICA) suppresses Aβ-mediated pathology in C. elegans.","date":"2018","source":"Experimental gerontology","url":"https://pubmed.ncbi.nlm.nih.gov/29709515","citation_count":17,"is_preprint":false},{"pmid":"37879938","id":"PMC_37879938","title":"MICA: a multi-omics method to predict gene regulatory networks in early human embryos.","date":"2023","source":"Life science alliance","url":"https://pubmed.ncbi.nlm.nih.gov/37879938","citation_count":16,"is_preprint":false},{"pmid":"29528990","id":"PMC_29528990","title":"NKG2D Immunoligand rG7S-MICA Enhances NK Cell-mediated Immunosurveillance in Colorectal Carcinoma.","date":"2018","source":"Journal of immunotherapy (Hagerstown, Md. : 1997)","url":"https://pubmed.ncbi.nlm.nih.gov/29528990","citation_count":16,"is_preprint":false},{"pmid":"25785062","id":"PMC_25785062","title":"MICA polymorphisms and cancer risk: a meta-analysis.","date":"2015","source":"International journal of clinical and experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25785062","citation_count":16,"is_preprint":false},{"pmid":"26862354","id":"PMC_26862354","title":"Associations of MICA Polymorphisms with Inflammatory Rheumatic Diseases.","date":"2015","source":"The open rheumatology journal","url":"https://pubmed.ncbi.nlm.nih.gov/26862354","citation_count":16,"is_preprint":false},{"pmid":"16274622","id":"PMC_16274622","title":"Distinct pattern of human Vdelta1 gammadelta T cells recognizing MICA.","date":"2005","source":"Cellular & molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/16274622","citation_count":16,"is_preprint":false},{"pmid":"28322797","id":"PMC_28322797","title":"Transcriptional activation of the MICA gene with an engineered CRISPR-Cas9 system.","date":"2017","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/28322797","citation_count":16,"is_preprint":false},{"pmid":"24997223","id":"PMC_24997223","title":"MICA/B expression in macrophage foam cells infiltrating atherosclerotic plaques.","date":"2014","source":"Experimental and molecular pathology","url":"https://pubmed.ncbi.nlm.nih.gov/24997223","citation_count":15,"is_preprint":false},{"pmid":"12190814","id":"PMC_12190814","title":"The increase in the frequency of MICA gene A6 allele in oral squamous cell carcinoma.","date":"2002","source":"Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology","url":"https://pubmed.ncbi.nlm.nih.gov/12190814","citation_count":15,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":50552,"output_tokens":6960,"usd":0.128028,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":16072,"output_tokens":6226,"usd":0.118005,"stage2_stop_reason":"end_turn"},"total_usd":0.246033,"stage1_batch_id":"msgbatch_01BbTCMyrRPyhtEq6b1MdwCN","stage2_batch_id":"msgbatch_011dEed5bbxYvTAaQWKJevxu","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2008,\n      \"finding\": \"MICA ectodomain shedding by tumor cells is mediated by ADAM10 and ADAM17 metalloproteases; silencing of ADAM10 or ADAM17 inhibited proteolytic release of soluble MICA from tumor cells, and the cleavage site maps to the stalk of the MICA ectodomain where deletions (but not alanine substitutions) impede shedding.\",\n      \"method\": \"siRNA knockdown of ADAM10/ADAM17 in tumor cell lines, small-molecule inhibitor/stimulator assays, ELISA for soluble MICA\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal genetic silencing of two proteases with direct biochemical readout, replicated across multiple tumor cell lines and confirmed with pharmacological inhibitors\",\n      \"pmids\": [\"18676862\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Antibodies targeting the MICA α3 domain (the site of proteolytic shedding) prevent loss of cell-surface MICA and MICB by human cancer cells and restore NKG2D-mediated NK cell immune surveillance; antitumor immunity was mediated mainly by NK cells through NKG2D and CD16 Fc receptors.\",\n      \"method\": \"Rational antibody design targeting α3 domain, in vitro shedding assays, multiple immunocompetent mouse tumor models, humanized mouse melanoma metastasis model, NK cell depletion experiments\",\n      \"journal\": \"Science (New York, N.Y.)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — multiple orthogonal methods (in vitro shedding inhibition, multiple in vivo models, mechanistic NK depletion), single rigorous study with strong evidence\",\n      \"pmids\": [\"29599246\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"MICA/NKG2D interaction directly mediates IEL cytotoxicity toward intestinal epithelial cells in celiac disease; gliadin (or its p31-49 peptide) induces MICA expression on gut epithelium via IL-15, which then triggers innate-like cytotoxicity and costimulates CD8 T cells through NKG2D engagement.\",\n      \"method\": \"In vitro gliadin challenge of intestinal epithelial cells, anti-MICA/NKG2D blocking antibodies, coculture cytotoxicity assays, patient biopsy analysis\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — blocking antibody experiments combined with cytotoxicity assays and patient tissue, multiple orthogonal approaches in one study\",\n      \"pmids\": [\"15357948\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"The MICA-129Met isoform (strong NKG2D binder) elicits stronger NKG2D signaling, more NK-cell degranulation and IFN-γ release, and faster CD8+ T-cell costimulation than MICA-129Val; MICA-129Met also induces faster and stronger NKG2D downregulation on NK and CD8+ T cells, limiting surface NKG2D levels.\",\n      \"method\": \"Functional NK cytotoxicity assays, IFN-γ ELISA, flow cytometry for NKG2D surface expression, clinical HSCT cohort (n=452)\",\n      \"journal\": \"EMBO molecular medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple functional assays (cytotoxicity, IFN-γ, NKG2D downregulation) combined with large clinical cohort validation\",\n      \"pmids\": [\"26483398\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"The MICA-129Met/Val dimorphism affects plasma membrane expression and shedding: MICA-129Met variants are retained more in intracellular compartments, and when expressed at the cell surface are more susceptible to proteolytic shedding, resulting in lower net surface MICA-129Met density despite higher mRNA levels.\",\n      \"method\": \"Flow cytometry for surface MICA on panel of tumor/melanoma cell lines, ELISA for soluble MICA, transfection of MICA-129Met and -Val constructs into MICA-negative melanoma cells, intracellular MICA staining\",\n      \"journal\": \"Immunogenetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple cell-biological methods in single lab, isogenic transfectant comparison provides mechanistic clarity\",\n      \"pmids\": [\"26585323\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"NF-κB regulates MICA transcription in endothelial cells via a defined control site at −130 bp upstream of the MICA transcription start site; TNFα-induced MICA upregulation is mediated through this NF-κB site, which overlaps with a heat shock response element integrating both pathways; lentiviral expression of a dominant-negative truncated HSF1 blocked the TNFα-driven MICA response.\",\n      \"method\": \"Reporter gene assays, site-directed mutagenesis of MICA promoter, ChIP, lentivirus-mediated gene delivery with dominant-negative HSF1 in primary human endothelial cells, immunohistochemistry of atherosclerotic lesions\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — promoter mutagenesis combined with dominant-negative functional rescue in primary cells, confirmed in patient tissue\",\n      \"pmids\": [\"22170063\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Decreased Dicer expression in human cells upregulates MICA and MICB via activation of the DNA damage response; MICA/B upregulation induced by Dicer knockdown was prevented by pharmacological or genetic inhibition of ATM, ATR, or CHK1, placing MICA/B induction downstream of DNA damage signaling.\",\n      \"method\": \"RNAi knockdown of Dicer, pharmacological inhibitors of ATM/ATR/CHK1, genetic epistasis with checkpoint kinase mutants, Western blot and flow cytometry for MICA/B\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis with multiple DNA damage pathway components, orthogonal pharmacological confirmation\",\n      \"pmids\": [\"18644891\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"MICA-induced NKG2D downregulation on human NK cells is mechanistically distinct from ULBP2-induced downregulation: MICA (but not ULBP2) engages the ubiquitin pathway and the E3 ligase c-Cbl to drive NKG2D internalization and lysosomal/proteasomal degradation.\",\n      \"method\": \"Comparison of MICA vs. ULBP2 stimulation of NK cells, c-Cbl siRNA knockdown, ubiquitin pathway inhibitors, flow cytometry for NKG2D surface expression and internalization, cytotoxicity assays\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA knockdown of c-Cbl with functional NKG2D readout, single lab, two orthogonal methods\",\n      \"pmids\": [\"24846123\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Mutations designed to destabilize the unbound (disordered) region of MICA—rather than to stabilize the receptor-bound conformation—increased the NKG2D association rate and binding affinity by 0.9–1.8 kcal/mol; kinetic changes were primarily observed during association, consistent with the disordered-to-ordered conformational transition upon receptor binding.\",\n      \"method\": \"RosettaDesign computational mutagenesis, recombinant protein expression, surface plasmon resonance (SPR) kinetics and thermodynamics\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution with SPR kinetics and thermodynamic analysis on 15+ MICA mutants, single lab but rigorous biophysical approach\",\n      \"pmids\": [\"17690100\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"MICA expression on T lymphocytes is induced by T cell activation signals: engagement of CD3 or CD28 (with PMA) upregulates MICA protein and mRNA in both CD4+ and CD8+ T cells, as detected by Western blot, RT-PCR, and flow cytometry; activation reaches plateau at day 3–4.\",\n      \"method\": \"Anti-CD3 and anti-CD28 antibody stimulation, Western blot, RT-PCR, flow cytometry for surface MICA\",\n      \"journal\": \"Journal of leukocyte biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — three orthogonal detection methods (Western, RT-PCR, flow cytometry) in single lab\",\n      \"pmids\": [\"11994503\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Activated CD4+ T lymphocytes retain MICA predominantly in intracellular compartments (visualized by confocal microscopy), resulting in low surface MICA expression; this intracellular retention appeared to protect activated CD4+ T cells from NKG2D-mediated NK cell killing, as MICA contribution to NK cytotoxicity was marginal despite inducible MICA protein expression.\",\n      \"method\": \"Confocal microscopy for intracellular MICA localization, NK cytotoxicity assays with anti-MICA blocking, Western blot, flow cytometry\",\n      \"journal\": \"Human immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — direct localization by confocal microscopy with functional NK cytotoxicity readout, single lab\",\n      \"pmids\": [\"16698439\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"ERp5 (a thiol oxidoreductase) and GRP78, when translocated to the cell surface on chronic lymphocytic leukemia (CLL) cells, co-localize with MICA and are involved in proteolytic MICA shedding; pharmacological inhibition of ERp5 activity reduced soluble MICA release from CLL cells.\",\n      \"method\": \"Immunofluorescence and flow cytometry co-localization, correlation analysis, pharmacological ERp5 inhibition, ELISA for soluble MICA\",\n      \"journal\": \"Cancer immunology, immunotherapy : CII\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — co-localization plus pharmacological inhibition providing functional link, single lab\",\n      \"pmids\": [\"22215138\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Tumor-derived exosomes bearing MICA (and other NKG2D ligands) reduce the proportion of NKG2D-expressing CD8+ T cells and CD3− effector cells and impair NKG2D-dependent cytotoxicity; blocking NKG2D ligands on exosomes with antibodies reversed this inhibition, establishing that exosomal MICA mediates immune evasion.\",\n      \"method\": \"Incubation of PBL with tumor exosomes, flow cytometry for NKG2D surface expression, anti-NKG2D ligand antibody blocking, in vitro cytotoxicity assays\",\n      \"journal\": \"Blood cells, molecules & diseases\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — antibody blocking experiments on exosome-treated effector cells, functional cytotoxicity assay, single lab\",\n      \"pmids\": [\"15885603\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Hypoxia downregulates cell-surface MICA on osteosarcoma cells in a HIF-1α-dependent manner without increasing soluble MICA; siRNA knockdown of HIF-1α under hypoxia restored surface MICA expression and concomitantly increased soluble MICA, placing HIF-1α upstream of MICA suppression.\",\n      \"method\": \"Hypoxia chamber culture (1% O2), siRNA knockdown of HIF-1α, flow cytometry for surface MICA, ELISA for soluble MICA, NK cytotoxicity assay\",\n      \"journal\": \"International journal of oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic knockdown of HIF-1α with multiple readouts (surface MICA, soluble MICA, NK killing), single lab\",\n      \"pmids\": [\"22992985\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"The MICA*008 A5.1 frameshift allele causes 7–10-fold higher MICA mRNA and surface protein expression on endothelial cells and shifts MICA release exclusively to exosomes rather than enzymatic (metalloproteinase) cleavage; A5.1 endothelial cells elicit enhanced NKG2D interaction and NK-cell-mediated lysis.\",\n      \"method\": \"Comparative expression analysis of A5.1 vs. wild-type EC, RT-PCR, Western blot, flow cytometry, NKG2D binding assay, NK cytotoxicity assay, exosome isolation\",\n      \"journal\": \"Journal of the American Society of Nephrology : JASN\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods comparing isogenic variant, single lab\",\n      \"pmids\": [\"23539759\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"MICA expression is regulated by purine nucleotide metabolism: active glycolysis and purine synthesis are necessary to upregulate MICA, and increases in purine nucleotide levels alone are sufficient to induce MICA expression, with metabolic induction of MICA directly increasing NKG2D-dependent cytotoxicity.\",\n      \"method\": \"Metabolic interventions (glucose deprivation, glycolysis inhibitors, purine synthesis inhibitors), metabolomic analyses, flow cytometry for surface MICA, NK cytotoxicity assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple metabolic perturbations with MICA expression and functional cytotoxicity readouts, single lab\",\n      \"pmids\": [\"29279329\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"MICA can mediate NKG2D-independent suppression of T cell proliferation; this suppressive effect requires IL-10 and involves a receptor other than NKG2D.\",\n      \"method\": \"T cell proliferation assays with MICA-expressing stimulator cells, NKG2D blocking antibodies, IL-10 neutralization/addition, genetic NKG2D-deficient cells\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — NKG2D blocking and IL-10 neutralization in proliferation assays establishing NKG2D-independent pathway, single lab\",\n      \"pmids\": [\"16091471\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Estradiol upregulates MICA expression on uterine epithelial cells in an estrogen receptor-dependent manner; MICA protein was detected primarily on endometrial epithelial cells with greater expression in the secretory phase of the menstrual cycle.\",\n      \"method\": \"Estradiol treatment of uterine epithelial cells, estrogen receptor antagonist blocking, real-time PCR, immunohistochemistry of endometrial biopsies\",\n      \"journal\": \"Clinical immunology (Orlando, Fla.)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — estrogen receptor antagonist establishes receptor dependence, corroborated by tissue immunohistochemistry, single lab\",\n      \"pmids\": [\"18728002\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"The HCMV protein UL147A specifically downregulates the most prevalent MICA allele, MICA*008, by inducing its maturation arrest and additionally targeting it for proteasomal degradation; UL147A specificity for MICA*008 is determined by the non-canonical GPI anchoring pathway used by immature MICA*008.\",\n      \"method\": \"HCMV infection of cells expressing MICA*008 vs. other alleles, UL147A expression constructs, flow cytometry for surface MICA, proteasome inhibitor assays, mechanistic analysis of GPI pathway dependence\",\n      \"journal\": \"PLoS pathogens\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — allele-specific knockdown, mechanistic pathway dissection (maturation arrest + proteasomal degradation + GPI pathway), proteasome inhibitor rescue, multiple orthogonal methods\",\n      \"pmids\": [\"33939764\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"The MICA/B antibody 7C6 (targeting the α3 domain to inhibit shedding) promotes macrophage-mediated antibody-dependent phagocytosis of AML cells as the primary mechanism of antitumor efficacy; romidepsin (HDAC inhibitor) increased MICA/B surface expression and synergized with 7C6 to enhance macrophage phagocytosis and reduce leukemia burden.\",\n      \"method\": \"Macrophage depletion in mouse AML models, antibody-dependent phagocytosis assays, MICA/B expression by flow cytometry following romidepsin treatment, humanized AML mouse model, primary patient AML cells\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — macrophage depletion epistasis, phagocytosis assays, drug combination studies, in vivo and humanized models, multiple orthogonal methods\",\n      \"pmids\": [\"34359073\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"MUC1-C represses MICA and MICB expression through NF-κB-driven EZH2-mediated and DNMT-mediated methylation of the MICA/B promoter regions; MUC1-C also regulates ERp5 (required for MICA/B protease digestion and shedding) and interacts with RAB27A (required for exosome formation), thereby controlling both shedding and exosomal MICA/B secretion.\",\n      \"method\": \"Genetic and pharmacological MUC1-C targeting (GO-203 inhibitor), co-immunoprecipitation for MUC1-C/ERp5 and MUC1-C/RAB27A interactions, direct binding studies, ChIP for H3K27me3 and DNA methylation at MICA/B promoters, ELISA for shed MICA/B, exosome isolation and characterization, NK cytotoxicity assays\",\n      \"journal\": \"Journal for immunotherapy of cancer\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — multiple orthogonal mechanisms (epigenetic, shedding, exosomal) each validated by distinct methods (ChIP, Co-IP, direct binding, functional rescue), single rigorous study\",\n      \"pmids\": [\"36754452\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"ADAM17 is the primary MICA sheddase in hepatocellular carcinoma cells; ADAM17 siRNA knockdown reduced soluble MICA levels and increased membrane-bound MICA; lomofungin enzymatically inhibits ADAM17 and dose-dependently restores membrane MICA while reducing soluble MICA shedding, with effects abolished by ADAM17 knockdown.\",\n      \"method\": \"siRNA knockdown of ADAM family members, ELISA for soluble MICA, flow cytometry for membrane MICA, in vitro ADAM17 enzymatic inhibition assay with FDA-approved drug library, structure-activity analysis of lomofungin analogs\",\n      \"journal\": \"International journal of cancer\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — enzymatic assay plus genetic rescue (knockdown abolishes drug effect), multiple cell lines, SAR analysis\",\n      \"pmids\": [\"29873070\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"MicroRNAs of the miR-25-93-106b cluster suppress MICA expression in HCC cells; overexpression of this miRNA cluster significantly reduced MICA protein levels, while silencing enhanced MICA expression, with biologically significant effects on NKG2D binding and in vivo NK cell killing.\",\n      \"method\": \"miRNA overexpression and inhibition in HCC cells, Western blot for MICA, NKG2D-binding assay, in vivo cell-killing model\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — bidirectional miRNA manipulation (overexpression and inhibition) with functional NKG2D and in vivo readouts, single lab\",\n      \"pmids\": [\"24061441\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"MICA antigens stimulate T cell proliferation and CD8+ T cell-mediated cytotoxicity in a manner dependent on MHC class I and II molecules but independent of NKG2D; immunization with recombinant MICA elicited a predominantly Th2-type CD4+ T cell response (IL-4 dominant), and MICA-stimulated CD8+ T cells killed MICA-primed target cells.\",\n      \"method\": \"Mouse immunization with rMICA, [3H]thymidine proliferation assay, CFSE proliferation tracking, cytokine ELISA, MHC class I/II and NKG2D blocking antibodies, cytotoxicity assay\",\n      \"journal\": \"Human immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — antibody blocking of MHC and NKG2D receptors establishes pathway independence, multiple readouts, single lab\",\n      \"pmids\": [\"16698445\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Endothelial cell MICA expression and shedding are regulated by inflammatory cytokines and proliferative signals: TNFα upregulates surface MICA via NF-κB and MAPK pathways (JNK, ERK1/2, p38); IFNγ decreases surface MICA; both cytokines induce soluble MICA release; FGF-2-driven EC proliferation and wound healing increase surface MICA levels. Glycosylation and metalloproteinase activity are major post-transcriptional mechanisms controlling MICA on ECs.\",\n      \"method\": \"Cytokine treatment of ECs, NF-κB and MAPK pathway inhibitors, metalloproteinase inhibitors, glycosylation inhibitors, flow cytometry for surface MICA, ELISA for soluble MICA, proliferation assays\",\n      \"journal\": \"Journal of innate immunity\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple pathway inhibitors with MICA expression and shedding readouts, single lab\",\n      \"pmids\": [\"23860405\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"IL-2 induces MICA expression in T lymphocytes through signaling pathways involving Jak3/STAT5, p38 MAPK, p70S6 kinase, Lck/Fyn kinases, and NF-κB, as demonstrated by targeted pharmacological inhibition of each pathway.\",\n      \"method\": \"Pharmacological inhibition of Jak3, STAT5, p38 MAPK, p70S6K, Lck/Fyn, and NF-κB in IL-2-stimulated T cells; Western blot for MICA protein\",\n      \"journal\": \"Human immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — pharmacological inhibition of multiple signaling nodes with MICA protein readout, single lab\",\n      \"pmids\": [\"16698439\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"MICA is a stress-inducible MHC class I-related cell-surface glycoprotein that serves as the principal ligand for the activating receptor NKG2D on NK cells, γδ T cells, and CD8+ T cells; its surface expression is transcriptionally upregulated by NF-κB (via TNFα), estradiol, purine metabolic activity, DNA damage (ATM/ATR/CHK1 pathway), and T cell activation signals (CD3/CD28), while being repressed by HIF-1α (under hypoxia), IL-10, and the MUC1-C→EZH2/DNMT epigenetic axis; proteolytic shedding of the MICA ectodomain by ADAM10, ADAM17, and other ADAMs generates immunosuppressive soluble MICA that downregulates NKG2D and enables tumor immune evasion, with shedding further regulated by ERp5 and modulated by the MICA-129Met/Val dimorphism (Met variant shows higher NKG2D binding but greater intracellular retention and surface shedding); MICA-induced NKG2D internalization and degradation is mediated specifically by the E3 ubiquitin ligase c-Cbl, distinguishing MICA from other NKG2D ligands; viral immune evasion of MICA is exemplified by HCMV UL147A, which arrests maturation of the predominant MICA*008 allele and targets it for proteasomal degradation via its non-canonical GPI-anchoring pathway.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"MICA is a stress-inducible cell-surface ligand for the activating immunoreceptor NKG2D that couples cellular stress states to NK-cell, \\u03b3\\u03b4 T-cell, and CD8+ T-cell cytotoxicity, functioning as a central node in immune surveillance of transformed, infected, and inflamed cells [#2, #15]. Engagement of NKG2D by MICA drives degranulation, IFN-\\u03b3 release, and target killing, with the natural MICA-129Met/Val dimorphism tuning the strength of this output: the Met variant binds NKG2D more strongly and elicits faster signaling but also drives more rapid NKG2D downregulation [#3]. Structurally, NKG2D binding involves a disordered-to-ordered transition of MICA, and mutations that destabilize the unbound state accelerate association and raise affinity [#8]. MICA expression is controlled at multiple levels: it is transcriptionally upregulated by NF-\\u03baB downstream of TNF\\u03b1 through a defined promoter element overlapping a heat-shock response element [#5], by DNA-damage signaling through the ATM/ATR/CHK1 axis [#6], by purine nucleotide metabolism and glycolysis [#15], by T-cell activation and IL-2 signaling [#9, #25], and by estradiol in endometrial epithelium [#17], while being repressed by HIF-1\\u03b1 under hypoxia [#13], by miR-25-93-106b [#22], and by the MUC1-C\\u2192NF-\\u03baB\\u2192EZH2/DNMT epigenetic axis [#20]. A dominant route of immune evasion is proteolytic shedding of the MICA ectodomain at its \\u03b13/stalk region by ADAM10 and ADAM17, generating soluble MICA that downregulates NKG2D; shedding requires the thiol oxidoreductase ERp5 and is governed by MUC1-C, which also controls exosomal MICA release via RAB27A [#0, #11, #20, #21]. MICA additionally contributes to disease pathology, mediating intestinal epithelial cytotoxicity in celiac disease through IL-15-driven induction and NKG2D engagement [#2]. Antibodies targeting the \\u03b13 shedding site restore surface MICA and reactivate antitumor immunity through NK-cell NKG2D/CD16 effector functions and macrophage-mediated phagocytosis [#1, #19]. Viral evasion is exemplified by HCMV UL147A, which arrests maturation of the prevalent MICA*008 allele and routes it for proteasomal degradation via its non-canonical GPI-anchoring pathway [#18].\",\n  \"teleology\": [\n    {\n      \"year\": 2002,\n      \"claim\": \"Established that MICA is not constitutively fixed but is induced as a marker of lymphocyte activation, defining it as a regulated stress/activation ligand rather than a static surface protein.\",\n      \"evidence\": \"Anti-CD3/CD28 stimulation of CD4+/CD8+ T cells with Western blot, RT-PCR, and flow cytometry\",\n      \"pmids\": [\"11994503\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Does not define the transcription factors linking TCR signaling to the MICA promoter\", \"Surface versus intracellular distribution of induced MICA not resolved\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Demonstrated that MICA/NKG2D engagement directly drives tissue pathology, linking MICA induction to intestinal epithelial destruction in celiac disease.\",\n      \"evidence\": \"Gliadin challenge of intestinal epithelium, IL-15 dependence, anti-MICA/NKG2D blocking, coculture cytotoxicity, patient biopsies\",\n      \"pmids\": [\"15357948\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Transcriptional mechanism of IL-15-driven MICA induction not detailed\", \"Does not address shedding or soluble MICA in this context\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Revealed two routes by which MICA suppresses immunity beyond direct activation: exosome-borne MICA downregulates effector NKG2D, and a distinct NKG2D-independent, IL-10-dependent pathway suppresses T-cell proliferation.\",\n      \"evidence\": \"Tumor exosome incubation with PBL plus antibody blocking; MICA stimulator cells with NKG2D blocking and IL-10 neutralization\",\n      \"pmids\": [\"15885603\", \"16091471\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Identity of the non-NKG2D MICA receptor unknown\", \"Mechanism of MICA loading onto exosomes not defined\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Showed MICA can act as an immunogen engaging adaptive responses through MHC class I/II independent of NKG2D, and that activated CD4+ T cells sequester MICA intracellularly to evade NK killing.\",\n      \"evidence\": \"rMICA immunization with proliferation/cytotoxicity assays and MHC/NKG2D blocking; confocal microscopy of intracellular MICA with NK cytotoxicity\",\n      \"pmids\": [\"16698445\", \"16698439\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of intracellular retention not defined\", \"Adaptive MICA antigen presentation pathway not molecularly mapped\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Defined the biophysical basis of MICA-NKG2D recognition, showing the unbound MICA surface is disordered and that the association step is rate-limiting via a disorder-to-order transition.\",\n      \"evidence\": \"RosettaDesign mutagenesis of 15+ mutants with SPR kinetics and thermodynamics\",\n      \"pmids\": [\"17690100\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vitro biophysics only; cellular relevance of designed mutants untested\", \"Does not address allelic affinity differences in physiological context\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Identified ADAM10 and ADAM17 as the proteases that shed MICA at its stalk, establishing the molecular machinery of soluble MICA generation and tumor immune evasion.\",\n      \"evidence\": \"Reciprocal siRNA knockdown of ADAM10/ADAM17, inhibitor assays, stalk deletion mapping, soluble MICA ELISA\",\n      \"pmids\": [\"18676862\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not define what triggers protease engagement of MICA\", \"Relative contribution of each ADAM across tissues unresolved\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Connected MICA induction to genome-instability sensing and to hormonal control, showing DNA damage signaling (ATM/ATR/CHK1) and estrogen-receptor signaling each upregulate MICA.\",\n      \"evidence\": \"Dicer knockdown with ATM/ATR/CHK1 inhibition and epistasis; estradiol treatment of uterine epithelium with ER antagonist and immunohistochemistry\",\n      \"pmids\": [\"18644891\", \"18728002\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Transcription factors executing DNA-damage-driven MICA induction not identified\", \"Estrogen-responsive promoter elements not mapped\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Mapped a defined NF-\\u03baB control site at -130 bp mediating TNF\\u03b1-driven MICA transcription and showed it integrates with heat-shock signaling, providing a transcriptional mechanism for inflammatory MICA induction.\",\n      \"evidence\": \"Promoter reporter assays, site-directed mutagenesis, ChIP, dominant-negative HSF1 in primary endothelial cells, atherosclerotic lesion immunohistochemistry\",\n      \"pmids\": [\"22170063\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not address how this site interacts with other inducers (DNA damage, metabolism)\", \"Cell-type generality of the -130 element beyond endothelium not tested\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Established additional shedding and repression mechanisms: ERp5/GRP78 surface translocation enables MICA shedding on CLL cells, and HIF-1\\u03b1 suppresses surface MICA under hypoxia.\",\n      \"evidence\": \"Co-localization and ERp5 pharmacological inhibition with soluble MICA ELISA; hypoxia culture with HIF-1\\u03b1 siRNA and surface/soluble MICA readouts\",\n      \"pmids\": [\"22215138\", \"22992985\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism linking ERp5 redox activity to ADAM cleavage not defined\", \"HIF-1\\u03b1 acts transcriptionally or post-transcriptionally on MICA not resolved\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Showed allele- and regulator-specific control of MICA fate, with the MICA*008 A5.1 frameshift diverting release to exosomes and the miR-25-93-106b cluster post-transcriptionally suppressing MICA.\",\n      \"evidence\": \"Comparative A5.1 vs wild-type endothelial expression with NK assays; bidirectional miRNA manipulation in HCC with NKG2D-binding and in vivo killing\",\n      \"pmids\": [\"23539759\", \"24061441\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Determinants channeling A5.1 MICA to exosomes versus protease cleavage not defined\", \"Direct miRNA-MICA mRNA binding sites not mapped\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Integrated endothelial MICA regulation, showing TNF\\u03b1 upregulates MICA via NF-\\u03baB/MAPK while IFN\\u03b3 lowers it, with glycosylation and metalloproteinase activity as dominant post-transcriptional controls.\",\n      \"evidence\": \"Cytokine treatment of endothelial cells with NF-\\u03baB/MAPK, metalloproteinase, and glycosylation inhibitors; surface and soluble MICA readouts\",\n      \"pmids\": [\"23860405\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Specific MAPK targets on the MICA promoter not identified\", \"Glycosylation sites controlling MICA stability not mapped\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Distinguished MICA from other NKG2D ligands mechanistically, showing MICA uniquely recruits the ubiquitin pathway and c-Cbl to drive NKG2D internalization and degradation.\",\n      \"evidence\": \"MICA vs ULBP2 NK stimulation, c-Cbl siRNA, ubiquitin pathway inhibitors, NKG2D internalization flow cytometry, cytotoxicity\",\n      \"pmids\": [\"24846123\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct c-Cbl substrate ubiquitination of NKG2D not biochemically demonstrated\", \"Why MICA but not ULBP2 engages c-Cbl is unexplained\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Defined the functional consequences of the MICA-129Met/Val dimorphism, linking the Met variant's stronger NKG2D binding to faster signaling but greater NKG2D downregulation, intracellular retention, and shedding.\",\n      \"evidence\": \"NK cytotoxicity/IFN-\\u03b3 assays, NKG2D flow cytometry, HSCT cohort (n=452); isogenic Met/Val transfectants with surface/soluble/intracellular MICA readouts\",\n      \"pmids\": [\"26483398\", \"26585323\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of Met-driven intracellular retention not defined\", \"Interaction of dimorphism with allele-specific shedding routes unresolved\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Linked metabolic state to immune visibility, showing glycolysis and purine nucleotide synthesis are necessary and sufficient to induce MICA and enhance NKG2D-dependent killing.\",\n      \"evidence\": \"Metabolic inhibitors, metabolomics, surface MICA flow cytometry, NK cytotoxicity\",\n      \"pmids\": [\"29279329\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Signaling that couples purine levels to MICA transcription not identified\", \"Whether metabolic induction is transcriptional or post-transcriptional unresolved\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Provided proof-of-concept that blocking MICA shedding at the \\u03b13 domain restores immune surveillance, and confirmed ADAM17 as the dominant sheddase in hepatocellular carcinoma with a druggable inhibitor.\",\n      \"evidence\": \"Rational \\u03b13-domain antibody with in vitro shedding inhibition and multiple in vivo tumor models plus NK depletion; ADAM17 siRNA and lomofungin enzymatic inhibition with knockdown-abolished rescue\",\n      \"pmids\": [\"29599246\", \"29873070\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Tissue-specific dominance of ADAM17 vs ADAM10 not generalized\", \"Long-term resistance to shedding blockade not addressed\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Defined an allele-specific viral evasion mechanism in which HCMV UL147A exploits the non-canonical GPI-anchoring pathway of MICA*008 to arrest its maturation and trigger proteasomal degradation.\",\n      \"evidence\": \"HCMV infection across MICA alleles, UL147A constructs, surface MICA flow cytometry, proteasome inhibitor rescue, GPI pathway dependence analysis\",\n      \"pmids\": [\"33939764\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular interface between UL147A and immature MICA*008 not resolved\", \"Generalization to other MICA alleles using canonical anchoring not addressed\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Expanded the effector mechanism of MICA-targeting therapy, showing \\u03b13-domain antibody 7C6 acts primarily through macrophage antibody-dependent phagocytosis and synergizes with HDAC inhibition to raise MICA/B.\",\n      \"evidence\": \"Macrophage depletion in AML models, ADCP assays, romidepsin-induced MICA/B expression, humanized AML model, primary patient cells\",\n      \"pmids\": [\"34359073\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contribution of macrophage versus NK effector arms across tumor types unresolved\", \"Mechanism of romidepsin-driven MICA/B upregulation not molecularly defined\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Unified transcriptional repression, shedding, and exosomal secretion under a single oncogenic regulator, showing MUC1-C represses MICA/B via NF-\\u03baB/EZH2/DNMT methylation while controlling ERp5-dependent shedding and RAB27A-dependent exosomal release.\",\n      \"evidence\": \"MUC1-C genetic/pharmacological targeting, ChIP for H3K27me3 and DNA methylation, Co-IP and direct binding for MUC1-C/ERp5 and MUC1-C/RAB27A, soluble/exosomal MICA assays, NK cytotoxicity\",\n      \"pmids\": [\"36754452\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct recruitment of EZH2/DNMT to the MICA/B promoter by MUC1-C not structurally resolved\", \"Hierarchy among the three MUC1-C-controlled mechanisms in vivo not established\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The identity of the non-NKG2D MICA receptor mediating IL-10-dependent T-cell suppression and the molecular determinants that select between protease shedding versus exosomal release remain unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No molecular identification of the NKG2D-independent MICA receptor\", \"Switch governing exosomal versus enzymatic MICA release not defined\", \"Integration of the many transcriptional inducers/repressors at the MICA locus not unified\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [2, 3, 8]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [2, 3]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 3, 13, 14]},\n      {\"term_id\": \"GO:0031410\", \"supporting_discovery_ids\": [12, 14, 20]},\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [0, 11, 21]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [1, 2, 3, 19]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [18, 20, 2]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [5, 20]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"NKG2D\", \"ADAM10\", \"ADAM17\", \"ERp5\", \"c-Cbl\", \"MUC1-C\", \"RAB27A\", \"GRP78\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"tie","faith_supported":8,"faith_total":8,"faith_pct":100.0}}